Zobrazeno 1 - 10
of 153
pro vyhledávání: '"Scott S, Tykodi"'
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 12 (2024)
Tumor-associated endothelial cells (TECs) are crucial mediators of immune surveillance and immune escape in the tumor microenvironment (TME). TECs driven by angiogenic growth factors form an abnormal vasculature which deploys molecular machinery to s
Externí odkaz:
https://doaj.org/article/260e213f809045e5ad192a635db49c20
Autor:
Chris P. Miller, Megan Fung, Carla A. Jaeger-Ruckstuhl, Yuexin Xu, Edus H. Warren, Shreeram Akilesh, Scott S. Tykodi
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 46, Iss , Pp 100948- (2023)
Metastatic renal cell carcinoma (RCC) remains an incurable disease for most patients highlighting an urgent need for new treatments. However, the preclinical investigation of new therapies is limited by traditional two-dimensional (2D) cultures which
Externí odkaz:
https://doaj.org/article/9a6a0ba591d64c2b98c9db933ac8344f
Autor:
Shailender Bhatia, Ramesh Rengan, Sylvia M Lee, Scott S Tykodi, Jing Zeng, Mary Redman, Peter H Goff, Kelsey K Baker
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/be0ed318d898496dbd1c082506d1fcd6
Autor:
Yuanquan Yang, Sarah P. Psutka, Anish B. Parikh, Mingjia Li, Katharine Collier, Abdul Miah, Sherry V. Mori, Megan Hinkley, Scott S. Tykodi, Evan Hall, John A. Thompson, Ming Yin
Publikováno v:
Cancer Medicine, Vol 11, Iss 16, Pp 3106-3114 (2022)
Abstract Background Immune checkpoint inhibitor/tyrosine kinase inhibitor (ICI/TKI) combinations are a new standard of care for the initial treatment of metastatic renal cell carcinoma (mRCC). Their efficacy and toxicity beyond the first‐line setti
Externí odkaz:
https://doaj.org/article/5a0bc07a3300429c841ed05a5967d215
Autor:
Scott S. Tykodi, Renate Pichler
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
Externí odkaz:
https://doaj.org/article/2178d36828204ecfae6423980d98e10a
Autor:
Chung-Wei Lee, Thomas Powles, Sabina Signoretti, Sumanta K Pal, Toni K Choueiri, Brian I Rini, Saby George, Robert J Motzer, Frede Donskov, Scott S Tykodi, Nizar M Tannir, Saurabh Gupta, Ruiyun Jiang
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 12 (2022)
Background Patients with advanced renal cell carcinoma with sarcomatoid features (sRCC) have a poor prognosis and limited therapeutic options. First-line nivolumab plus ipilimumab (NIVO+IPI) provided efficacy benefits over sunitinib (SUN) in patients
Externí odkaz:
https://doaj.org/article/635447aa98714bc2a7c7b60e0478a8aa
Autor:
Scott S Tykodi, Daniel J George, Jeff Yorio, Lucio N Gordan, Joshua Zhang, Jennifer L Johansen, Arash Rezazadeh Kalebasty, David R Spigel, Samith T Kochuparambil, Ana M Molina, Heidi McKean, Nishan Tchekmedyian, Margarita Askelson, Thomas E Hutson
Publikováno v:
BMJ Open, Vol 12, Iss 9 (2022)
Objectives The non-randomised, open-label, phase IIIb/IV multicohort CheckMate 920 trial explored the safety and efficacy with a less frequent, but continual nivolumab plus ipilimumab (NIVO+IPI) dosing regimen (cohort 1) to determine whether this mod
Externí odkaz:
https://doaj.org/article/a35e5923581b4b07b7b03b97b3b2d842
Autor:
Yuexin Xu, Alicia J. Morales, Andrea M. H. Towlerton, Shreeram Akilesh, Chris P. Miller, Scott S. Tykodi, Edus H. Warren
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Objective responses of metastatic renal cell carcinoma (RCC) associated with systemic immunotherapies suggest the potential for T-cell-mediated tumor clearance. Recent analyses associate clonally expanded T cells present in the tumor at diagnosis wit
Externí odkaz:
https://doaj.org/article/0138d642c53e44d4b870bb69d299c4c9
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 7, Pp 1882-1896 (2021)
In renal-cell carcinoma (RCC), tumor-reactive T-cell responses can occur spontaneously or in response to systemic immunotherapy with cytokines and immune checkpoint inhibitors. Cancer vaccines and engineered T-cell therapies are designed to selective
Externí odkaz:
https://doaj.org/article/fdeb72bf1a044f61940f92e772545845
Autor:
Thomas Hutson, Peter Van Veldhuizen, Michael R Harrison, Scott S Tykodi, Daniel J George, Lucio N Gordan, Robert S Alter, Edward Arrowsmith, Ivor Percent, Rakesh Singal, Joshua Zhang, Jesus Zoco, Jennifer L Johansen, Arash Rezazadeh Kalebasty
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 2 (2022)
Background CheckMate 920 (NCT02982954) is a multicohort, phase 3b/4 clinical trial of nivolumab plus ipilimumab treatment in predominantly US community-based patients with previously untreated advanced renal cell carcinoma (RCC) and clinical features
Externí odkaz:
https://doaj.org/article/2afaa38ab63544b783e82c3073c180bf